Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $6.8 million.

  • Legend Biotech's Change in Accured Expenses rose 552.75% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year decrease of 116.72%. This contributed to the annual value of $45.7 million for FY2024, which is 3587.94% up from last year.
  • As of Q3 2025, Legend Biotech's Change in Accured Expenses stood at $6.8 million, which was down 67.63% from $20.9 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Change in Accured Expenses ranged from a high of $77.0 million in Q4 2021 and a low of -$39.2 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $6.8 million (2025), whereas its average is $3.0 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 1,476.25% in 2023, then plummeted by 623.51% in 2025.
  • Over the past 5 years, Legend Biotech's Change in Accured Expenses (Quarterly) stood at $77.0 million in 2021, then tumbled by 97.73% to $1.7 million in 2022, then soared by 1,476.25% to $27.5 million in 2023, then slumped by 105.36% to -$1.5 million in 2024, then spiked by 552.75% to $6.8 million in 2025.
  • Its Change in Accured Expenses was $6.8 million in Q3 2025, compared to $20.9 million in Q2 2025 and -$38.6 million in Q1 2025.